This paper provides three recommendations to steer the potential effects of the IRA toward its goal of improving patient access while encouraging innovation.
The first study to examine biosimilar drivers finds commercial insurers limit use in almost 20% of cases.
We estimate the economic impacts of COVID-19 in the U.S. using a disaster economic consequence analysis framework implemented by a dynamic computable general equilibrium (CGE) model.
The cumulative social benefits from Medicare coverage for new obesity treatments over the next 10 years would reach almost $1 trillion, or roughly $100 billion per year.
Healthcare Markets Researchers
Nonresident Senior Fellow, USC Schaeffer Center
Former Assistant, U.S. President
Former Director, Domestic Policy Council (DPC)
Director, Research, USC Schaeffer Center
Quintiles Chair in Pharmaceutical Development and Regulatory Innovation, USC Mann School
Professor, USC Price School of Public Policy
Schaeffer Center Nonresident Senior Fellow and Former Director of the Domestic Policy Council Joe Grogan and AEI Senior Fellow and Former FDA Commissioner Scott Gottlieb joined Schaeffer Center Co-Director Erin Trish to discuss the challenges and opportunities facing the FDA and CMS in an age of breakthrough medical devices.Read Full Story
The Centers for Medicare and Medicaid Services refuses to approve breakthrough drugs.
The IRA will be measured not just by how much it can lower prices, but also by whether it continues to encourage drug makers to invest in new treatments.
CMS should abandon CED or, at minimum, reform and restrict its use only for off-label applications of therapies.
To make sure that CMS is getting its money’s worth for today’s drugs, it must ensure that the maximum fair price is aligned to drug value.
All told, in 2022 MA penetration reached 49.9% nationally, and 24% of Medicare beneficiaries with Parts A and B lived in a county with adjusted MA penetration equal to or exceeding 60%.Read Full Story
Learn more about HMI, including opportunities to collaborate